Therapies Born from the Science of Plasma®
Alkahest, a Grifols subsidiary, is a research and drug discovery company mining the deepest layers of plasma knowledge to inform the development of potential transformative therapies and solutions for patients.
Integrating Advanced Technology and Plasma Expertise
We leverage our experience in artificial intelligence and integrative analysis of multiomics and real-world data with our extensive plasma protein expertise.
An Evolving Protein Network
Our work is based on the scientific premise that the plasma proteome is constantly changing and influencing human biology. Multiple drivers of disease are linked to alterations in plasma proteins, with a difference in the concentration and/or conformation of those promoting health and those depleting it. Changes start occurring years before disease diagnosis and can provide clues for early biomarkers of disease to help predict, diagnose and treat disease.
Leveraging one of the World’s Largest Collections of Plasma
We have access to Grifols’ extensive repository of more than 100 million plasma samples collected for nearly 15 years. It contains plasma representing thousands of disease states connected to real-world health data. This comprehensive dataset, combined with our advanced analytical capabilities, positions us to drive breakthroughs in personalized medicine.
Targeting the Diseases of Our Future
| Product Indication | Research | IND Enabling | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
| WetAMD | |||||
| Parkinson's Disease (partnered with MJFF) | |||||
| Inflammatory Disease | |||||
| Alzheimer's Disease - Mild to Moderate | |||||
| Alzheimer's Disease - Severe | |||||
| Parkinson's Disease with Cognitive Impairment | |||||
| Postoperative Recovery | |||||
| End Stage Renal Disease related Cognitive Impairment | |||||
Novel Factors | |||||
| Undisclosed | |||||